TRANSFAC FACTOR TABLE, Release 2017.2 - public - 2017-06-30, (C) QIAGEN

AC T19129 XX ID T19129 XX DT 07.09.2006 (created); din. DT 27.08.2014 (updated); pos. CO Copyright (C), QIAGEN. XX FA NF-kappaB2 XX SY lyt; NF-kappaB2; NFKB2; Nuclear factor NF-kappa-B p100 subunit; nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, p49/p100; p49; p49/p100; p50B; p52. XX OS mouse, Mus musculus OC eukaryota; animalia; metazoa; chordata; vertebrata; tetrapoda; mammalia; eutheria; rodentia; myomorpha; muridae; murinae XX GE G009217 Nfkb2. XX CL C0020; Rel; XX IN T17574 NF-kappaB1-p50; mouse, Mus musculus. IN T09437 NF-kappaB1; mouse, Mus musculus. IN T00595 RelA-p65; mouse, Mus musculus. IN T01932 RelB; mouse, Mus musculus. IN T27517 RelB; Mammalia. XX MX M00774 V$NFKB_Q6_01. XX DR TRANSPATH: MO000086646. DR UniProtKB: Q9WTK5; Q9WTK5. XX RN [1]; RE0030779. RX PUBMED: 12556537. RA Muller J. R., Siebenlist U. RT Lymphotoxin beta receptor induces sequential activation of distinct NF-kappa B factors via separate signaling pathways. RL J. Biol. Chem. 278:12006-12 (2003). RN [2]; RE0030792. RX PUBMED: 12352969. RA Claudio E., Brown K., Park S., Wang H., Siebenlist U. RT BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. RL Nat. Immunol. 3:958-65 (2002). RN [3]; RE0043688. RX PUBMED: 12840022. RA Saitoh T., Nakayama M., Nakano H., Yagita H., Yamamoto N., Yamaoka S. RT TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation RL J. Biol. Chem. 278:36005-12 (2003). RN [4]; RE0044053. RX PUBMED: 15084608. RA Liao G., Zhang M., Harhaj E. W., Sun S. C. RT Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation RL J. Biol. Chem. 279:26243-50 (2004). RN [5]; RE0053534. RX PUBMED: 15755876. RA Hu J., Colburn N. H. RT Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding. RL Mol. Cancer Res. 3:100-109 (2005). RN [6]; RE0053586. RX PUBMED: 12387744. RA Kayagaki N., Yan M., Seshasayee D., Wang H., Lee W., French D. M., Grewal I. S., Cochran A. G., Gordon N. C., Yin J., Starovasnik M. A., Dixit V. M. RT BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. RL Immunity 17:515-524 (2002). RN [7]; RE0053762. RX PUBMED: 12874295. RA Maier H. J., Marienfeld R., Wirth T., Baumann B. RT Critical role of RelB serine 368 for dimerization and p100 stabilization. RL J. Biol. Chem. 278:39242-39250 (2003). RN [8]; RE0053794. RX PUBMED: 16609073. RA Deng W. G., Tang S. T., Tseng H. P., Wu K. K. RT Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. RL Blood 108:518-524 (2006). RN [9]; RE0053845. RX PUBMED: 12709443. RA Derudder E., Dejardin E., Pritchard L. L., Green D. R., Korner M., Baud V. RT RelB/p50 dimers are differentially regulated by tumor necrosis factor-alpha and lymphotoxin-beta receptor activation: critical roles for p100. RL J. Biol. Chem. 278:23278-23284 (2003). RN [10]; RE0053939. RX PUBMED: 12524526. RA Mordmuller B., Krappmann D., Esen M., Wegener E., Scheidereit C. RT Lymphotoxin and lipopolysaccharide induce NF-kappaB-p52 generation by a co-translational mechanism. RL EMBO Rep. 4:82-87 (2003). RN [11]; RE0054015. RX PUBMED: 15485634. RA Qian Y., Qin J., Cui G., Naramura M., Snow E. C., Ware C. F., Fairchild R. L., Omori S. A., Rickert R. C., Scott M., Kotzin B. L., Li X. RT Act1, a negative regulator in CD40- and BAFF-mediated B cell survival. RL Immunity 21:575-587 (2004). RN [12]; RE0054106. RX PUBMED: 9314550. RA Ishikawa H., Carrasco D., Claudio E., Ryseck R. P., Bravo R. RT Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-kappaB2. RL J. Exp. Med. 186:999-1014 (1997). RN [13]; RE0054133. RX PUBMED: 15148378. RA Zarnegar B., He J. Q., Oganesyan G., Hoffmann A., Baltimore D., Cheng G. RT Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-kappaB activation pathways. RL Proc. Natl. Acad. Sci. USA 101:8108-8113 (2004). RN [14]; RE0065739. RX PUBMED: 17548520. RA Reiley W. W., Jin W., Lee A. J., Wright A., Wu X., Tewalt E. F., Leonard T. O., Norbury C. C., Fitzpatrick L., Zhang M., Sun S. C. RT Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. RL J. Exp. Med. 204:1475-1485 (2007). RN [15]; RE0070799. RX PUBMED: 21084666. RA Xie P., Kraus Z. J., Stunz L. L., Liu Y., Bishop G. A. RT TNF receptor-associated factor 3 is required for T cell-mediated immunity and TCR/CD28 signaling. RL J. Immunol. 186:143-155 (2011). RN [16]; RE0072651. RX PUBMED: 21455180. RA Tokunaga F., Nakagawa T., Nakahara M., Saeki Y., Taniguchi M., Sakata S., Tanaka K., Nakano H., Iwai K. RT SHARPIN is a component of the NF-kappaB-activating linear ubiquitin chain assembly complex. RL Nature 471:633-636 (2011). XX //